DBV Technologies Announces Data Presentations For EPIT At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2014

BAGNEUX, France, March 25, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today that five scientific presentations of data related to its proprietary method, Epicutaneous Immunotherapy (EPITTM), have been selected with four as oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014 held in Copenhagen, Denmark, June 7-11.The abstracts will also be published in the June 2014 supplement of Allergy.

Help employers find you! Check out all the jobs and post your resume.